Lung cancer

Checkpoint inhibitors show potential for first line use in NSCLC


The next step for immune therapy in lung cancer is in combination with chemotherapy or radiotherapy as first line treatment, according to oncologist Associate Professor Chris Karapetis. Immune checkpoint inhibitors are listed on the PBS as second line treatments for non-small cell lung cancer (NSCLC) but the latest trials show their potential for use first ...

Already a member?

Login to keep reading.


OR
© 2018 the limbic